These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 1711007)

  • 1. Development of human anti-murine antibody (HAMA) response in patients.
    Tjandra JJ; Ramadi L; McKenzie IF
    Immunol Cell Biol; 1990 Dec; 68 ( Pt 6)():367-76. PubMed ID: 1711007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human antibody response to the intravenous and intraperitoneal administration of the F(ab')2 fragment of the OC125 murine monoclonal antibody.
    Maher VE; Drukman SJ; Kinders RJ; Hunter RE; Jennings J; Brigham C; Stevens S; Griffin TW
    J Immunother (1991); 1992 Jan; 11(1):56-66. PubMed ID: 1734949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA).
    Hosono M; Endo K; Sakahara H; Watanabe Y; Saga T; Nakai T; Kawai C; Matsumori A; Yamada T; Watanabe T
    Br J Cancer; 1992 Feb; 65(2):197-200. PubMed ID: 1739617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patients.
    Tibben JG; Thomas CM; Massuger LF; Segers MF; Schijf CP; Corstens FH; Boerman OC
    Nucl Med Commun; 1995 Oct; 16(10):853-9. PubMed ID: 8570116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of ELISAs for quantification of HMFG1-specific human anti-mouse IgG and IgM antibodies.
    Oei AL; Boerman OC; Geurts-Moespot A; van Eerd JE; van Tienoven D; Courtenay-Luck N; Thomas CM; Massuger LF; Sweep FC
    Int J Biol Markers; 2007; 22(3):167-71. PubMed ID: 17922458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in vitro and in vivo anti-tumour activity of N-AcMEL-(Fab')2 conjugates.
    Smyth MJ; Pietersz GA; McKenzie IF
    Br J Cancer; 1987 Jan; 55(1):7-11. PubMed ID: 3814478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-specific immunoglobulin interactions may lead to false-positive results in assays for human anti-mouse monoclonal antibodies (HAMA).
    Papoian R
    J Immunoassay; 1992; 13(2):289-96. PubMed ID: 1430244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.
    Cheung NK; Cheung IY; Canete A; Yeh SJ; Kushner B; Bonilla MA; Heller G; Larson SM
    Cancer Res; 1994 Apr; 54(8):2228-33. PubMed ID: 8174131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies.
    Dillman RO; Shawler DL; McCallister TJ; Halpern SE
    Cancer Biother; 1994; 9(1):17-28. PubMed ID: 7812354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms.
    Courtenay-Luck NS; Epenetos AA; Moore R; Larche M; Pectasides D; Dhokia B; Ritter MA
    Cancer Res; 1986 Dec; 46(12 Pt 1):6489-93. PubMed ID: 2430699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical trial of drug-monoclonal antibody conjugates in patients with advanced colorectal carcinoma: a preliminary report.
    Tjandra JJ; Pietersz GA; Teh JG; Cuthbertson AM; Sullivan JR; Penfold C; McKenzie IF; Smyth M
    Surgery; 1989 Sep; 106(3):533-45. PubMed ID: 2788931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
    Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
    Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-murine antibody response to mouse monoclonal antibodies in cancer patients.
    Sakahara H; Saga T; Onodera H; Yao Z; Nakamoto Y; Zhang M; Sato N; Nakada H; Yamashina I; Endo K; Konishi J
    Jpn J Cancer Res; 1997 Sep; 88(9):895-9. PubMed ID: 9369938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6.
    Legouffe E; Liautard J; Gaillard JP; Rossi JF; Wijdenes J; Bataille R; Klein B; Brochier J
    Clin Exp Immunol; 1994 Nov; 98(2):323-9. PubMed ID: 7955540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal analysis of a human antimouse antibody (HAMA) response.
    Thorpe SJ; Turner C; Heath A; Feavers I; Vatn I; Natvig JB; Thompson KM
    Scand J Immunol; 2003 Jan; 57(1):85-92. PubMed ID: 12542802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of anti-idiotypic antibodies and of their F(ab')2 fragments.
    Tassi V; Ruggiero G; Rosaia L; Lorenzoni P; Ceccarini C; Tecce MF
    Immunol Lett; 1991 Jan; 27(1):39-43. PubMed ID: 1708352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays.
    Buist MR; Kenemans P; van Kamp GJ; Haisma HJ
    Cancer Immunol Immunother; 1995 Jan; 40(1):24-30. PubMed ID: 7828165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines and idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg).
    Dietrich G; Pereira P; Algiman M; Sultan Y; Kazatchkine MD
    J Autoimmun; 1990 Oct; 3(5):547-57. PubMed ID: 1701301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
    Clark JI; Alpaugh RK; von Mehren M; Schultz J; Gralow JR; Cheever MA; Ring DB; Weiner LM
    Cancer Immunol Immunother; 1997 Jul; 44(5):265-72. PubMed ID: 9247561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.
    Miotti S; Negri DR; Valota O; Calabrese M; Bolhuis RL; Gratama JW; Colnaghi MI; Canevari S
    Int J Cancer; 1999 Feb; 84(1):62-8. PubMed ID: 9988234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.